on the last trading day of 2023, Haier group, which has already controlled Haier biology (688139.SH, stock price 40.52 yuan, market value 12.883 billion yuan) and yingkang life (300143.SZ, stock price 10.63 yuan, market value 6.826 billion yuan), has once again expanded its large health territory.

Haier Group will acquire 20% of the shares of Shanghai Laishi held by Kilifu for a total price of 12.5 billion RMB and obtain a total of 26.58 of the voting rights. After the reorganization of the board of directors is completed, Haier Group or its designated related parties will become the controlling shareholder of the company, and Haier Group will become the actual controller of the listed company.

12.5 billion Yuan Acquires Shanghai Rex

On the evening of December 29, Shanghai Laishi (002252.SZ, stock price 8 yuan, market value 53.164 billion yuan) announced that the company's shareholder Grifols,S.A.(hereinafter referred to as "Kilifu") and Haier Group Corporation (hereinafter referred to as "Haier Group") signed the "Strategic Cooperation and Share Purchase Agreement" on December 29, 2023. Haier Group or its designated related party intends to agree to acquire 1.329 billion shares of the company held by Kilifu, accounting for 20.00 of the company's total share capital, with a transfer price of 12.5 billion yuan. At the same time, Kiliford entrusted the voting rights corresponding to its remaining 0.437 billion shares of the Company to Haier Group or its designated affiliates, accounting for 6.58 of the Company's total share capital.

that is to say, based on the above strategic cooperation, Haier group will acquire 20% of the shares held by killifook in Shanghai Les for a total price of 12.5 billion RMB and obtain a total of 26.58 of the voting rights. In addition, after the completion of the transaction, Kiliford will continue to hold 6.58 percent of Shanghai Leishi shares and retain a seat on the board of directors.

The "Daily Business News" reporter noted that as a seller, Kilifu Group is mainly engaged in the production and sales of plasma products, diagnostic reagents, testing equipment and testing technology, and provides testing services. It is also the world's leading medical and health company. And plasma products manufacturer.

From the main business point of view, Shanghai RAAS is the production and sales of blood products, the main products are human albumin, intravenous human immunoglobulin, specific immunoglobulin, coagulation factor products, etc., is currently one of the leading enterprises in the production of blood products in China.

Although it is no longer the controlling party, the information disclosed by Shanghai Laishi shows that Kili Fu and Shanghai Laishi will reach a long-term strategic cooperation. After the completion of the transaction, the term of the exclusive albumin agency agreement signed by Kili Fu and Shanghai Laishi will be extended for ten years, and on this basis, the right to renew for ten years will be obtained. As a buyer, Haier Group, which is home appliances, is currently accelerating its layout in the field of large health.

Haier continues to lay out a big healthy track

In recent years, Haier has made great efforts to lay out the track of the big health industry, organically combining scientific and technological innovation with the big health industry, and has created the big health ecological brand of Yingkang.

The information provided by Haier to the reporter of ''Daily Economic News'' shows that Yingkang has been committed to the research and development, production and application of high-end scientific research equipment, medical devices and medical service solutions throughout its life., Preparation, cold chain transportation and clinical applications have formed an industrial ecology. This transaction will help Yingkang to further improve the layout of the blood ecological industry chain throughout its life, it is an important milestone in the development of Haier's health industry.

Tan Lixia, vice chairman of the board of directors and executive vice president of Haier Group, said: "the achievement of this strategic cooperation has further improved the layout of Yingkang's life-long blood industry chain. it is a key process for us to go deep into the core areas of medical and health. Shanghai RAISE's pursuit of safety, quality and innovation complements Haier's user-centric philosophy of excellence. We look forward to working closely with Shanghai Laishi and Kili Fu to enhance the integration and innovation of the blood ecological industry chain."

"China is at the heart of our growth strategy," said

Grifols Raimon, Chief Corporate Officer, Kilifook. "We are delighted to join forces with Haier, a global innovation leader, to share our commitment to innovation, quality and safety. With this partnership, we will be able to support the development of China's healthcare system with a better service offering innovative medicines and diagnostic solutions for patients."

It is worth noting that the transaction has been supported by the boards of directors of both parties and is expected to be completed in the first half of 2024. It is subject to customary closing conditions and is still subject to regulatory approval and relevant delivery conditions.

(cover image source: every reporter Zhang Jian photo)